Pcn172 - Cost-Effectiveness Analysis of Alectinib in Untreated Alk-Rearranged NSCLC Italian Patients

Value in Health- United Kingdom

doi 10.1016/j.jval.2018.09.255

Full Text

Abstract

Available in

Categories

Occupational Health

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Pcn82 - Budget Impact Analysis of Alectinib for the Treatment of Patients With Untreated Alk-Rearranged NSCLC in Italy

Value in Health

Occupational Health

English

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management

English

Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib

Journal of Community and Supportive Oncology

English

P1.13-04 Integrin Β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK Rearranged NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Alectinib Resistance in ALK-rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

Molecular Cancer Research

Cancer Research

Molecular Biology

English

Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey

Value in Health

Occupational Health

English

P1.01-35 Tumor Volume Analysis in ALK-Rearranged NSCLC Treated With Crizotinib: Identifying an Early Marker for Clinical Outcome

Journal of Thoracic Oncology

Respiratory Medicine

English

P044 Cost-Effectiveness Analysis of Icotinib vs Whole-Brain Irradiation in NSCLC Patients With Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcn141 - Cost-Effectiveness Analysis of Obinutuzumab for the Treatment of Patients With Previously Untreated Advanced Follicular Lymphoma in Greece

Value in Health

Occupational Health

English